Michael Ulz

Stock Analyst at Morgan Stanley

(0.39)
# 1696
Out of 5,293 analysts
160
Total ratings
37.93%
Success rate
5.25%
Average return
Main Sectors:
Top Industries:
45 Stocks
Name Action Price Target Current % Upside Ratings Updated
KYTX Kyverna Therapeutics
Maintains: Overweight
40 20
1.98 910.1% 2 Apr 1, 2025
CABA Cabaletta Bio
Maintains: Overweight
30 22
1.16 1796.55% 6 Apr 1, 2025
AARD Aardvark Therapeutics
Initiates Coverage On: Overweight
29
8.25 251.52% 1 Mar 10, 2025
YMAB Y-mAbs Therapeutics
Maintains: Underweight
11 7
4.5 55.56% 7 Mar 5, 2025
SLN Silence Therapeutics
Maintains: Overweight
49 45
2.42 1759.5% 11 Mar 5, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
75 54
3.55 1421.13% 5 Mar 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
24 20
3.25 515.38% 4 Feb 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
275 284
255.81 11.02% 9 Feb 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
20 5
3.37 48.37% 5 Feb 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
18 10
1.11 800.9% 2 Feb 3, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
46 96
38.63 148.51% 4 Jan 28, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
105 105
23.89 339.51% 2 Sep 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
48 52
9.22 463.99% 2 Aug 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
110 115
86 33.72% 9 Jul 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
53 57
44.04 29.43% 3 Jun 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
36 27
12.21 121.13% 4 May 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
47 65
n/a n/a 4 Apr 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
3 7
0.78 797.44% 8 Feb 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underweight
23 12
n/a n/a 4 Jan 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
45 48
27.25 76.15% 4 Nov 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
15 27
5.54 387.36% 2 Aug 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
42 37
n/a n/a 9 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
35 40
n/a n/a 4 May 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
30 20
3.2 525% 3 Mar 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
45
5.81 674.53% 1 Feb 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
20 10
0.68 1370.59% 3 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
6 8
0.22 3536.36% 5 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
3
1.26 138.1% 1 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Equal-Weight
18 30
6.18 385.44% 1 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
135 90
n/a n/a 3 Aug 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
15 7
n/a n/a 3 May 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
25 30
1.15 2508.7% 3 Mar 30, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Equal-Weight
n/a
n/a n/a 1 Feb 1, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
84 36
n/a n/a 2 Jan 5, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
45
5.63 699.29% 1 Oct 8, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
500
n/a n/a 1 Sep 23, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
12 20
0.33 5960.61% 2 May 28, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
30
n/a n/a 1 Apr 16, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
3 1
n/a n/a 4 Mar 29, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
7 4
n/a n/a 3 Oct 22, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
17 0
n/a n/a 2 Sep 21, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
680 544
n/a n/a 2 Jun 13, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
85 80
33.84 136.41% 2 Nov 3, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
12 15
7.95 88.68% 3 Jul 12, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
127 182
n/a n/a 2 Feb 27, 2017